The U.S. Food and Drug Administration has approved a new type of pain medication, Journavx, developed by Vertex Pharmaceuticals. This drug offers a potentially safer alternative to opioids for managing short-term pain, such as that experienced after surgery or injuries. Although its effectiveness is modest compared to opioid-acetaminophen combinations, Journavx's unique mechanism of action, which blocks pain signals before they reach the brain, holds promise for addressing the opioid crisis.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It's the first new pharmaceutical approach to treating pain in more than 20 years, offering an alternative to both opioids and over-the-counter medications like ibuprofen and acetaminophen.
\Studies in more than 870 patients with acute pain due to foot and abdominal surgeries showed Vertex's drug provided more relief than a dummy pill but didn't outperform a common opioid-acetaminophen combination pill. 'It's not a slam dunk on effectiveness,' said Michael Schuh of the Mayo Clinic, a pharmacist and pain medicine expert who was not involved in the research. 'But it is a slam dunk in that it's a very different pathway and mechanism of action. So, I think that shows a lot promise.' \The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids, which are often available as generics for $1 or less. Vertex began researching the drug in the 2000s, when overdoses were rocketing upward, principally driven by mass prescribing of opioid painkillers for common ailments like arthritis and back pain. Prescriptions have fallen sharply in the last decade and the current wave of the opioid epidemic is mainly due to illicit fentanyl, not pharmaceutical medicines. Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids' addictive effects. Vertex's drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. 'In trying to develop medicines that don't have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,' Vertex's Dr. David Altshuler, told The Associated Press last year. 'The new medication has side effect profiles that are inherently, not only different, but don't involve the risk of substance abuse and other key side effects associated with opioids,' said Dr. Charles Argoff of the Albany Medical Center, who consulted for Vertex on the drug's development. The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary condition that causes insensitivity to pain. Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally represents a bigger financial opportunity than acute pain. But the Boston drugmaker's share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs. The drug didn't perform significantly better than placebo, the research found. 'We believe the data reflect a near worst-case scenario for this key pipeline program,' biotechnology analyst Brian Abrahams said in a research note to investors, adding that the results jeopardized estimates that Vertex's pipeline could be worth billions across multiple forms of pain. Still, Vertex executives said they plan to move forward with a new, late-stage study of the drug, theorizing that a different trial design could yield better results and pave the way for FDA approval in chronic pain
PAIN MANAGEMENT OPIOIDS FDA APPROVAL NEW DRUG VERTEX PHARMACEUTICALS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
FDA Approves New Nonopioid Pain Killer JournavxThe FDA has approved a new nonopioid painkiller, Journavx, for moderate to severe acute pain in adults. This could potentially reduce opioid prescriptions after surgery or provide an alternative for those who can't tolerate other pain medications.
Read more »
FDA Approves First New Pain Drug in Over 20 YearsThe U.S. Food and Drug Administration has approved Journavx, a new type of pain medication developed by Vertex Pharmaceuticals, marking the first significant advancement in pain treatment in over two decades. Journavx offers a non-opioid alternative for managing short-term pain, potentially addressing the ongoing opioid crisis.
Read more »
FDA Approves First New Pain Drug in 20 Years, Aimed at Avoiding Opioid RisksThe U.S. Food and Drug Administration has approved Journavx, a new pain medication developed by Vertex Pharmaceuticals, marking the first significant advancement in pain management pharmaceuticals in over two decades. Journavx offers a non-opioid alternative for treating short-term pain typically associated with surgery or injuries. While initial studies indicate modest effectiveness compared to opioid-acetaminophen combinations, the drug's unique mechanism of action, which blocks pain signals before they reach the brain, holds promise for addressing the ongoing opioid crisis.
Read more »
FDA Approves First New Pain Drug in Over 20 YearsA new type of pain medication designed to avoid the risks associated with opioids has been approved by the U.S. Food and Drug Administration. Vertex Pharmaceuticals' Journavx targets short-term pain following surgery or injuries.
Read more »